There was exciting news in the field of bladder cancer treatment at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA. Speaking from the meeting, Alison Birtle, MRCP, FRCR, MD, of Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK, discusses the findings from the POUT trial (NCT01993979), a Phase III randomized study that determined the efficacy and the safety of adjuvant chemotherapy following radical nephroureterectomy, as well as its effect on the quality of life, for patients with upper tract urothelial carcinoma (UTUC). With such promising data from the POUT trial, Dr Birtle expresses her hopes of adjuvant chemotherapy becoming the standard of care for patients with UTUC.
POUT trial: a new standard of care for upper tract urothelial carcinoma
